Navigation Links
INBRACED awards $400,000 grant to launch an international neuroblastoma clinical trial
Date:5/22/2014

Solving Kids' Cancer, the Neuroblastoma Children's Cancer Alliance (NCCA UK), and Joining Against Cancer in Kids (J-A-C-K) awarded its first grant through their INBRACED (International Neuroblastoma Research and Collaboration for Effective Delivery) initiative, which aims to improve access of promising clinical trials for children with high-risk neuroblastoma in North America, the UK and in Europe. The grant amount of $400,000 will create a new immunotherapy treatment option in the U.S., UK, and in Spain, for children with relapsed or refractory disease. The international phase I clinical trial will use a vaccine that targets the GD2 and GD3 antigens, which has already shown promising results in children with neuroblastoma in the U.S.

The low-toxicity vaccine was developed by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, which is participating in the trial alongside Bristol Children's Hospital in the UK, and the Hospital Sant Joan de Du Barcelona, in Spain. The vaccine utilizes a child's own immune system to help the body recognize and destroy cancer cells that express the two antigens most commonly found on the surface of neuroblastoma cellsGD2 and GD3, potentially promoting long-term remissions in these children. A phase I trial with this same vaccine was recently completed at MSKCC with 15 patients and demonstrated very promising results; the results were published in the March 2014 issue of Clinical Cancer Research.

This is the first international clinical trial for children with cancer that has been initiated and sponsored solely by pediatric cancer nonprofits. "The success of this new partnership lies in the amazing determination of UK and U.S. charities, parents, research institutions, doctors and pharmaceutical organization to help more children survive," said Bettina Bungay-Balway, Chief Executive of the London-based NCCA UK.

"We truly hope this will speed the exploration and evolution of potential therapies for the children and their families blighted by neuroblastoma," said Richard Brown, Chair at J-A-C-K.

Neuroblastoma is a cancer of the sympathetic nervous system that most commonly occurs in infants and children under five. The cancer is usually discovered after it has spread. Half of all children diagnosed have high-risk neuroblastoma, one of the most aggressively treated of all childhood cancers. Unfortunately, even after intense chemotherapy and radiation, the cancer often returns in many children. Immunotherapy clinical trials have shown dramatic results in adults and in children with leukemia in the U.S., but such novel options are limited in the UK and in Europe.

"All families should have access to novel experimental treatment options and not have to travel across continents or go in debt for a chance to treat their child," said Scott Kennedy, the Executive Director of Solving Kids' Cancer. "Our goal as part of INBRACED is to have the leading cancer centers in the U.S., U.K., and Europe collaborate on clinical trials to develop treatments with the highest potential for cures."


'/>"/>

Contact: Jenny
jenny@solvingkidscancer.org
212-588-6625
Solving Kids' Cancer
Source:Eurekalert

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards
3. Washingtons Life Sciences Discovery Fund awards commercialization grants
4. Awards celebrate clinical research that can improve health and alleviate suffering
5. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
6. Awards to 5 IU School of Medicine physicians address critical need for geriatricians
7. Biomedical researchers receive Hartwell Foundation awards
8. Lawson researcher receives 1 of first-ever Pfizer Psychiatry Research Awards
9. AGA announces prestigious awards recognition recipients
10. US Army internal medicine residents receive awards from American College of Physicians
11. Outstanding high school students receive awards to stimulate research interest in digestive diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Highlands Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... particularly over the past 35 years. A president has access to health and wellness ... leader of the free world, no single individual has a schedule as frenetic as ...
(Date:2/12/2016)... ... ... The Central Coast Autism Spectrum Center (CCASC) invites teens ages 11-18 to its annual Winter ... teens with and without special needs to gather in a safe and supportive environment. Volunteers ... will take place on Saturday, Feb. 13 from 7 to 9:30 p.m. at Elks Lodge, ...
(Date:2/12/2016)... ... 12, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... he says are the real facts surrounding all those Bible stories. For generations families ... school teachers, and Yisrayl says there is more to these than just mere “stories”. ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Planet ... Studios. The new cartoon style themes are great for showcasing pictures, videos as well ... scene generators, titles like introductions, lower thirds, transitions and a beautiful frame overlay. Pixel ...
(Date:2/12/2016)... ... February 12, 2016 , ... Dignity Health named Dr. Scott Bingham the ... The new facility is licensed under Dignity Health Arizona General Hospital , ... excellent leader and will ensure our new freestanding emergency room delivers the highest quality ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 --> ... Inflammation Global Clinical Trials Review, H2, 2015 provides ... clinical trials landscape along with top level data ... (G7 & E7), Trial Status, Trial Phase, Sponsor ... companies involved and enlists all trials (Trial title, ...
(Date:2/11/2016)... The primary goal of this research is to analyze ... of liquid biopsy. Key information the survey seeks to ... liquid biopsy adoption amidst future users - Predominantly used ... Sample inflow to conduct liquid biopsy tests - Preference ... on. - Correlation analysis of sample type and biomarker ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
Breaking Medicine Technology: